ASCO-GU-2024

Jan 25

-

Jan 27, 2024

The ENZAMET phase 3 trial aimed to investigate the impact of enzalutamide, focusing on radiographic progression without PSA in mHSPC. Researchers observed worse overall survival in mHSPC participants with radiographic progression without prior PSA progression. ENZAMET, a randomized trial comparing enzalutamide (ENZA) to a standard non-steroidal anti-androgen (NSAA) in 1125 metastatic hormone-sensitive prostate […]...

Advertisement

Advertisement

SELECT ONCOLOGY JOURNAL ARTICLES

First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS >=1%: results from a multicenter, open-label, phase 2 trial

First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS >=1%: results from a multicenter, open-label, phase 2 trial

Background The combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety of camrelizumab plus famitinib (a receptor tyrosine kinase …

Early Experience With Two-Fraction Spine Stereotactic Body Radiation Therapy in Treating Spinal Metastases

Early Experience With Two-Fraction Spine Stereotactic Body Radiation Therapy in Treating Spinal Metastases

Introduction: Spinal metastases are common in metastatic cancer, affecting around 40% of patients. The primary treatment involves radiation therapy, transitioning from conventional external beam radiation therapy (EBRT) to stereotactic body radiation therapy (SBRT) for its …